Business Medical Dialogues
    • facebook
    • twitter
    Login Register
    • facebook
    • twitter
    Login Register
    • Medical Dialogues
    • Speciality Dialogues
    • Education Dialogues
    • Medical Jobs
    • Medical Matrimony
    • MD Brand Connect
    Business Medical Dialogues
    • News
        • Financial Results
        • Hospitals & Diagnostics
        • IT / Health Venture
        • Implants / Devices
        • Insurance
        • Key Movement
        • Pharmaceuticals
        • Policy
        • Technology
        • pharma-news
    • blog
    LoginRegister
    Business Medical Dialogues
    LoginRegister
    • Home
    • News
      • Financial Results
      • Hospitals & Diagnostics
      • IT / Health Venture
      • Implants / Devices
      • Insurance
      • Key Movement
      • Pharmaceuticals
      • Policy
      • Technology
      • pharma-news
    • blog
    • Home
    • News
    • Implants / Devices
    • Govt rejects Abbott,...

    Govt rejects Abbott, Medtronic applications to withdraw stents

    Written by Ruby Khatun Khatun Published On 2017-04-27T15:29:34+05:30  |  Updated On 16 Aug 2021 3:45 PM IST



    New Delhi: The government on Wednesday rejected applications by multinational firms Abbott Healthcare Pvt Ltd and India Medtronic Pvt Ltd to withdraw their advanced coronary stents from India while asking them to maintain supplies of the products.

    In a notification on Wednesday, the national pharmaceutical pricing authority (NPPA) asked the companies to consider options for price revision before deciding to withdraw their products from the market. Last week Abbott had sought permission to withdraw its "alpine drug eluting" stent and "absorb dissolving" stent, while Medtronic had also sought to withdraw its Onyx Zotarolimus eluting stents in the wake of the government bringing the medical device under price control earlier this year.

    On 21 February, the government had invoked emergency clause of DPCO 2013, citing public interest and asked stent manufacturers, distributors and suppliers to maintain supplies of their products for six months. In a notification on Wednesday, the NPPA said during the period no such request from the companies to withdraw their products could be entertained.

    The NPPA said the companies would be "free to resubmit" their requests two weeks before the expiry of the restrictions, which are currently in operation. When contacted, an Abbott Healthcare spokesperson said that the company is reviewing the memorandum issued by the NPPA. The drug price regulator also asked the two companies to explore options of price revision provided under various rules before exercising "an exit route". It also asked Abbott and Medtronic "to be more cautious and responsible in taking such business decisions in the light of government's commitment to ensure affordability and availability of all essential drugs to the people".

    The NPPA also said the two companies did not comply with the government's direction to give weekly reports on the availability of stents. In February, the NPPA had brought stents under price control and capped ceiling price of coronary stents at Rs7,260 for bare metal variety and Rs29,600 for drug-eluting ones. The corresponding average MRPs before the price control stood at Rs45,100 and Rs1.21 lakh, respectively. Last month, the drug price regulator increased price of stents by around 2% after taking into account the wholesale price index.


    AbbottAbsorb dissolving stentAlpineCoronary StentsDrug Eluting StentMedtronicNational Pharmaceutical Pricing AuthorityNPPAOnyx ZotarolimusRejectionStentwithdrawal
    Source : PTI

    Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd

    Ruby Khatun Khatun
    Ruby Khatun Khatun
      Show Full Article
      Next Story
      Similar Posts
      NO DATA FOUND

      Popular Stories

      • Email: info@medicaldialogues.in
      • Phone: 011 - 4372 0751

      Website Last Updated On : 13 Oct 2022 5:14 AM GMT
      Company
      • About Us
      • Contact Us
      • Our Team
      • Reach our Editor
      • Feedback
      • Submit Article
      Ads & Legal
      • Advertise
      • Advertise Policy
      • Terms and Conditions
      • Privacy Policy
      • Editorial Policy
      • Comments Policy
      • Disclamier
      Medical Dialogues is health news portal designed to update medical and healthcare professionals but does not limit/block other interested parties from accessing our general health content. The health content on Medical Dialogues and its subdomains is created and/or edited by our expert team, that includes doctors, healthcare researchers and scientific writers, who review all medical information to keep them in line with the latest evidence-based medical information and accepted health guidelines by established medical organisations of the world.

      Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription.Use of this site is subject to our terms of use, privacy policy, advertisement policy. You can check out disclaimers here. © 2025 Minerva Medical Treatment Pvt Ltd

      © 2025 - Medical Dialogues. All Rights Reserved.
      Powered By: Hocalwire
      X
      We use cookies for analytics, advertising and to improve our site. You agree to our use of cookies by continuing to use our site. To know more, see our Cookie Policy and Cookie Settings.Ok